Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros

Banco de datos
Tipo del documento
Publication year range
1.
Obstet Gynecol ; 114(2 Pt 1): 300-309, 2009 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-19622991

RESUMEN

OBJECTIVES: Grafts are used for vaginal repair after prolapse, but their use to carry stem cells to regenerate vaginal tissue has not been reported. In this study, we investigated whether 1) muscle-derived stem cells (MDSC) grown on small intestinal submucosa (SIS) generate smooth-muscle cells (SMC) in vitro and upon implantation in a rat model of vaginal defects; 2) express markers applicable to the in-vivo detection of vaginal endogenous stem cells; and 3) stimulate the repair of the vagina. METHODS: Mouse MDSC grown on monolayer, SIS, or polymeric mesh, were tested for cell differentiation by immunocytochemistry, Western blot and real-time polymerase chain reaction (PCR). Stem cell markers were screened by DNA microarrays followed by real-time PCR, immunocytochemistry, and Western blot. Rats that underwent hysterectomy and partial vaginectomy were left as such or implanted in the vagina with 4',6-Diamidino-2-Phenylindole (DAPI)-labeled MDSC on SIS, or SIS without MDSC, immunosuppressed, and killed at 2-8 weeks. Immunofluorescence, hematoxylin-eosin, and Masson trichrome were applied to tissue sections. RESULTS: Muscle-derived stem cell cultures on monolayer and on scaffolds differentiate into SMC, as shown by alpha-smooth muscle actin (ASMA), calponin, and smoothelin markers. Muscle-derived stem cells express embryonic stem cell markers Oct-4 and nanog. Dual DAPI/ASMA fluorescence indicated MDSC conversion to SMC. Muscle-derived stem cells/SIS stimulated vaginal tissue repair, including keratin-5 positive epithelium formation and prevented fibrosis at 4 and 8 weeks. Oct-4+ putative endogenous stem cells were identified. CONCLUSION: Muscle-derived stem cells/SIS implants stimulate vaginal tissue repair in the rat, thus autologous MDSC on scaffolds may be a promising approach for the treatment of vaginal repair.


Asunto(s)
Trasplante de Células Madre/métodos , Andamios del Tejido , Vagina/cirugía , Animales , Células Cultivadas , Femenino , Mucosa Intestinal , Intestino Delgado , Ratones , Ratones Endogámicos C57BL , Células Musculares/citología , Miocitos del Músculo Liso/citología , Ratas , Ratas Endogámicas F344 , Trasplante Heterólogo , Prolapso Uterino/cirugía
2.
Menopause ; 21(6): 612-23, 2014 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-24281237

RESUMEN

OBJECTIVE: This study aims to determine the dose-dependent effects of testosterone on sexual function, body composition, muscle performance, and physical function in hysterectomized women with or without oophorectomy. METHODS: Seventy-one postmenopausal women who previously underwent hysterectomy with or without oophorectomy and had total testosterone levels less than 31 ng/dL or free testosterone levels less than 3.5 pg/mL received a standardized transdermal estradiol regimen during the 12-week run-in period and were randomized to receive weekly intramuscular injections of placebo or 3, 6.25, 12.5, or 25 mg of testosterone enanthate for 24 weeks. Total and free testosterone levels were measured by liquid chromatography-tandem mass spectrometry and equilibrium dialysis, respectively. The primary outcome was change in sexual function measured by the Brief Index of Sexual Functioning for Women. Secondary outcomes included changes in sexual activity, sexual distress, Derogatis Interview for Sexual Functioning, lean body mass, fat mass, muscle strength and power, and physical function. RESULTS: Seventy-one women were randomized; five groups were similar at baseline. Sixty-two women with analyzable data for the primary outcome were included in the final analysis. The mean on-treatment total testosterone concentrations were 19, 78, 102, 128, and 210 ng/dL in the placebo, 3-mg, 6.25-mg, 12.5-mg, and 25-mg groups, respectively. Changes in composite Brief Index of Sexual Functioning for Women scores, thoughts/desire, arousal, frequency of sexual activity, lean body mass, chest-press power, and loaded stair-climb power were significantly related to increases in free testosterone concentrations; compared with placebo, changes were significantly greater in women assigned to the 25-mg group, but not in women in the lower-dose groups. Sexual activity increased by 2.7 encounters per week in the 25-mg group. The frequency of androgenic adverse events was low. CONCLUSIONS: Testosterone administration in hysterectomized women with or without oophorectomy for 24 weeks was associated with dose and concentration-dependent gains in several domains of sexual function, lean body mass, chest-press power, and loaded stair-climb power. Long-term trials are needed to weigh improvements in these outcomes against potential long-term adverse effects.


Asunto(s)
Andrógenos/administración & dosificación , Histerectomía , Sexualidad/efectos de los fármacos , Testosterona/análogos & derivados , Testosterona/sangre , Andrógenos/efectos adversos , Nivel de Alerta/efectos de los fármacos , Composición Corporal/efectos de los fármacos , Relación Dosis-Respuesta a Droga , Femenino , Humanos , Persona de Mediana Edad , Fuerza Muscular/efectos de los fármacos , Músculo Esquelético/efectos de los fármacos , Músculo Esquelético/fisiología , Ovariectomía , Posmenopausia , Conducta Sexual/efectos de los fármacos , Testosterona/administración & dosificación , Testosterona/efectos adversos
3.
Curr Opin Obstet Gynecol ; 19(5): 469-73, 2007 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-17885464

RESUMEN

PURPOSE OF REVIEW: This review discusses published data of the recent advances in understanding lower urinary tract dysfunctions in women with diabetes mellitus. RECENT FINDINGS: Many studies have shown a relationship between diabetes mellitus and lower urinary tract dysfunctions. Although the pathophysiology of these disorders is multifactorial, microvascular damage and neuropathy causing dysfunctions of smooth muscle, urothelium, and neuronal components in the lower urinary tract are the most likely etiologies. SUMMARY: Lower urinary tract dysfunctions are common in diabetes mellitus. Screening and effective management of these disorders should be promoted in an effort to decrease morbidity and improve quality of life.


Asunto(s)
Complicaciones de la Diabetes/etiología , Complicaciones de la Diabetes/patología , Diabetes Mellitus/patología , Enfermedades de la Vejiga Urinaria/etiología , Enfermedades de la Vejiga Urinaria/patología , Animales , Femenino , Ginecología/métodos , Humanos , Estilo de Vida , Microcirculación , Músculo Liso/metabolismo , Músculo Liso/patología , Neuronas/metabolismo , Calidad de Vida , Vejiga Urinaria/patología , Vejiga Urinaria Neurogénica/patología , Urotelio/patología
SELECCIÓN DE REFERENCIAS
Detalles de la búsqueda